Mumps disease: Malacards - Research Articles, Symptoms, Drugs, Genes, Clinical Trials

MedlinePlus:³⁵ Mumps is an illness caused by the mumps virus. it starts with fever headache muscle aches tiredness loss of appetite after that, the salivary glands under the ears or jaw become swollen and tender. the swelling can be on one or both sides of the face. symptoms last 7 to 10 days. serious complications are rare. you can catch mumps by being with another person who has it. there is no treatment for mumps, but the measles-mumps-rubella (mmr) vaccine can prevent it. before the routine vaccination program in the united states, mumps was a common illness in infants, children and young adults. now it is a rare disease in the u.s. centers for disease control and prevention

MalaCards based summary: Mumps is related to encephalitis and congenital mumps, and has symptoms including fever, headache and muscle aches. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways are Osteoclast differentiation and Immune response IFN gamma signaling pathway. Affiliated tissues include salivary gl, salivary gland and brain, and related mouse phenotypes are liver/biliary system and endocrine/exocrine gland.

Disease Ontology:¹⁰ A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC:² Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Wikipedia:⁶⁸ Mumps, also known as epidemic parotitis, is a viral disease caused by the mumps virus. Initial signs and... more...

Related Diseases for Mumps

Sources:
²⁰GeneCards, ¹⁹GeneAnalytics
See all MalaCards sources

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)

id	Related Disease	Score	Top Affiliating Genes
1	encephalitis	31.2	STAT1, STAT2
2	congenital mumps	12.1
3	rubella	11.1
4	measles	11.1
5	photokeratitis	10.6	IFNG, STAT1
6	non-distal monosomy 10q	10.6	HLA-DRB1, IFNG
7	red cell phospholipid defect with hemolysis	10.6	HLA-DRB1, IFNG
8	scleritis	10.6	CD40LG, STAT1
9	beriberi	10.6	CD40LG, IFNG
10	bacillary angiomatosis	10.6	CD40LG, IFNG
11	demyelinating polyneuropathy	10.6	IFNG, STAT1
12	pityriasis rosea	10.6	CD40LG, HLA-DRB1
13	louping ill	10.5	CD40LG, IFNG
14	pulmonary nodular lymphoid hyperplasia	10.5	HLA-DRB1, IFNG
15	myofascial pain syndrome	10.5	HLA-DRB1, IFNG, STAT1
16	cycloplegia	10.4	IFNG, IL2RA
17	lujo hemorrhagic fever	10.4	HLA-DRB1, IL6
18	lower gum cancer	10.4	IFNG, IRF2
19	graft-versus-host disease, protection against	10.4	IFNG, IL2RA
20	chronic hiccups	10.4	IFNG, IL2RA
21	orchitis	10.4
22	endotheliitis	10.4
23	plasma protein metabolism disease	10.4	CD40LG, IL6
24	meningitis	10.4
25	b cell deficiency	10.4	CD40LG, IFNG
26	cytoplasmic body myopathy	10.3	HLA-DRB1, IFNG
27	wrinkles	10.3	CD40LG, IL6
28	acute hemorrhagic leukoencephalitis	10.3
29	acute disseminated encephalomyelitis	10.3
30	intestinal impaction	10.3	CD40LG, IL6
31	limited scleroderma	10.3	CD40LG, HLA-DRB1, IFNG
32	aseptic meningitis	10.3
33	early-onset, autosomal dominant alzheimer disease	10.3	IFNG, IL6
34	angioid streaks	10.3	HLA-DRB1, IL2RA
35	refractory plasma cell neoplasm	10.3	CD40LG, IL6
36	parotitis	10.3
37	cd3delta deficiency	10.2	IL12RB2, IL2RA
38	motion sickness	10.2	IFNG, IL6, STAT1
39	penile disease	10.2	IFNG, IL2RA
40	leukoplakia of penis	10.2	IFNG, IL12RB2, IL18R1
41	vulvar disease	10.2	IFNG, IL2RA, STAT1
42	collagenous colitis	10.2	HLA-DRB1, IFNG, IL6
43	hypercementosis	10.2	HLA-DRB1, IFNG, IL2RA
44	skin conditions	10.2	IL12RB2, IL6
45	inflammatory leiomyosarcoma	10.2	CD40LG, HLA-DRB1, IL6
46	keratomalacia	10.2	CD40LG, HLA-DRB1, IL6
47	lateral sclerosis	10.2	CD40LG, HLA-DRB1, IL6
48	pupil disease	10.2	HLA-DRB1, IFNG, IL6
49	congenital dyserythropoietic anemia	10.2	CD40LG, IFNG, IL6
50	meige syndrome	10.1	CD40LG, IFNG, IL6

Graphical network of the top 20 diseases related to Mumps:

Symptoms for Mumps

Sources:
¹⁰Disease Ontology, ⁶⁵UMLS
See all MalaCards sources

Symptoms:

¹⁰

fever
headache
muscle aches

tiredness
loss of appetite
swollen

UMLS symptoms related to Mumps:

pruritus

Drugs & Therapeutics for Mumps

Sources:
⁴⁴NIH Clinical Center, ⁴ClinicalTrials, ⁶Cochrane Library, ⁶⁵UMLS, ⁴³NDF-RT, ¹³DrugBank, ²⁶HMDB, ⁹DGIdb, ⁵³PharmGKB, ³⁰IUPHAR, ⁴⁷Novoseek, ¹BitterDB
See all MalaCards sources

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)

id

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Pharmaceutical Solutions

Phase 4, Phase 3, Phase 2

7004

2

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4, Phase 3, Phase 2

440

3

Antibodies

Phase 4, Phase 2, Phase 1

4477

4

Vaccines

Phase 4, Phase 3, Phase 2, Phase 1, Phase 0

6085

5

Immunologic Factors

Phase 4, Phase 3, Phase 2, Phase 1

18483

6

Immunoglobulins

Phase 4, Phase 2, Phase 1

4477

7

Liver Extracts

Phase 4

3572

8

Aluminum hydroxide

approved

Phase 3, Phase 2

178

Synonyms:

Al(OH)3

Aluminiumhydroxid

Aluminum Hydroxide

Aluminum hydroxide

Dermadrox

9

PENTA

Phase 3, Phase 2

109

10

Lactitol

Phase 3, Phase 2

320

585-86-4

3871

Synonyms:

4-O-b-D-Galactopyranosyl-D-glucitol, 9CI

E966

Emportal

Floralac

Importal

Oponaf

Portolac

11

Daclizumab

approved, investigational

Phase 2

96

152923-56-3

Synonyms:

Anti-IL-2

Humanized antiCD25

Ig gamma-1 chain C region

Simulect

chimeric mouse-human antiCD25

12

Altretamine

approved

Phase 2

57

645-05-6

2123

Synonyms:

2,4, 6-Tris(dimethylamino)-1,3,5-triazine

2,4,6-Tris(dimethylami

2,4,6-Tris(dimethylamino)-1,3,5-triazine

2,4,6-Tris(dimethylamino)-S-triazine

2,4,6-Tris(dimethylamino)-s-triazine

2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine

549835_ALDRICH

645-05-6

A 8723

A0567/0026158

A8723_SIGMA

AB00052308

AC-12006

AC1L1CYX

AI3-50852

AKOS001729401

Altretamin

Altretamina

Altretamina [INN-Spanish]

Altretamine (USP/INN)

Altretamine Bellon Brand

Altretamine Chiesi Brand

Altretamine Wassermann Brand

Altretamine [USAN:INN:BAN]

Altretaminum

Altretaminum [INN-Latin]

Altrétamine

BPBio1_001004

BRD-K67043667-001-04-1

BRN 0195058

BSPBio_000912

Bellon Brand of Altretamine

C9H18N6

CAS-654-05-6

CCRIS 5492

CHEBI:24564

CHEMBL1455

CID2123

CPD000058181

ChemDiv2_005185

Chiesi Brand of Altretamine

D006585

D02841

DB00488

DivK1c_000772

EINECS 211-428-4

ENT 50852

EU-0100083

FT-0083576

HEXAMETHYLMELAMINE

HMM

HMS1383L15

HMS1570N14

HMS1922C05

HMS2090G17

HMS2092H16

HMS502G14

HSDB 7559

HTM

HXM

Hemel

Hexalen

Hexalen (TN)

Hexalen, Altretamine

Hexamethylmelamine

Hexastat

Hexinawas

I06-0604

IDI1_000772

IDI1_003900

InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H

KB-913

KBio1_000772

KBio2_001788

KBio2_004356

KBio2_006924

KBio3_002042

KBioGR_001388

KBioSS_001788

LS-1549

Lopac-A-8723

Lopac0_000083

MGI Pharma Brand of Altretamine

MLS000069621

MLS001076123

MolPort-002-111-210

N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine

NC 195

NCGC00015100-01

NCGC00015100-02

NCGC00015100-03

NCGC00015100-06

NCGC00015100-11

NCGC00021216-03

NCGC00021216-04

NCGC00021216-05

NCGC00021216-06

NCGC00021216-07

NCI-C50259

NCI60_000871

NINDS_000772

NSC 13875

NSC-13875

NSC13875

N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine

Prestwick0_000946

Prestwick1_000946

Prestwick2_000946

Prestwick3_000946

Rhone Poulenc Rorer Brand of Altretamine

Rhone-Poulenc Rorer Brand of Altretamine

S1278_Selleck

SAM002564241

SMR000058181

SPBio_000754

SPBio_003071

SPECTRUM1503065

ST086739

STK749184

Spectrum2_000907

Spectrum3_000951

Spectrum4_001064

Spectrum5_001092

Spectrum_001308

UNII-Q8BIH59O7H

WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1

Wassermann Brand of Altretamine

ZINC00000905

altretamine

no)-s-triazine

13

Interleukin-2

Phase 2

487

14

Immunosuppressive Agents

Phase 2

10422

15

Antibodies, Monoclonal

Phase 2

2413

16

Azathioprine

approved

153

446-86-6

2265

Synonyms:

446-86-6

55774-33-9 (hydrochloride salt)

6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine

6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine

6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine

6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine

6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine

6-(1-Methyl-4-nitroimidazol-5-ylthio)purin

6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]

6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine

6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine

6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine

6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine

6-(Methyl-p-nitro-5-imidazolyl)-thiopurine

6-(Methyl-p-nitro-5-imidazolyl)thiopurine

6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine

6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine

6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine

6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine

6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine

6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine

6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine

6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine

A 4638

A2593_SIAL

A4638_SIAL

A4638_SIGMA

AB00443544

AB00443544-03

AC-4230

AC1L1DAL

AC1Q3Z1F

AI-981/34845012

AI3-50290

Azamun

Azamun [Czech]

Azanin

Azasan

Azasan (TN)

Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine

Azathioprin

Azathioprine

Azathioprine (JP15/USP/INN)

Azathioprine Sodium

Azathioprine [USAN:INN:BAN:JAN]

Azathioprine sodium

Azathioprinum

Azathioprinum [INN-Latin]

Azathiopurine

Azatioprin

Azatioprina

Azatioprina [INN-Spanish]

Azothioprine

B. W. 57-322

BPBio1_000054

BRD-K32821942-001-05-6

BRD-K60324116-001-01-5

BSPBio_000048

BSPBio_001876

BW 57-322

BW 57322

BW-57-322

C06837

C9H7N7O2S

CAS-446-86-6

CBDivE_013132

CCRIS 62

CHEBI:2948

CHEMBL1542

CID2265

CPD000427366

Ccucol

ChemDiv1_002659

Cytostatics

D00238

DB00993

DivK1c_000586

EINECS 207-175-4

EU-0100027

FT-0083532

HMS1568C10

HMS1920E17

HMS2091K19

HMS501N08

HMS594I19

HSDB 7084

IDI1_000586

Immuran

Imuran

Imuran (TN)

Imuran (tn)

Imurek

Imurel

KBio1_000586

KBio2_000464

KBio2_002427

KBio2_003032

KBio2_004995

KBio2_005600

KBio2_007563

KBio3_001376

KBio3_002906

KBioGR_000646

KBioGR_002427

KBioSS_000464

KBioSS_002433

LS-123

Lopac-A-4638

Lopac0_000027

MLS001049307

Methylnitroimidazolylmercaptopurine

MolPort-000-745-914

MolPort-000-764-262

MolPort-003-665-485

Muran

NCGC00015060-01

NCGC00015060-02

NCGC00015060-04

NCGC00015060-12

NCGC00090836-01

NCGC00090836-02

NCGC00090836-03

NCGC00090836-04

NCGC00090836-05

NCGC00090836-06

NCGC00094593-01

NCGC00094593-02

NCGC00094593-03

NCI-C03474

NINDS_000586

NSC 39084

NSC-39084

NSC39084

Oprea1_375441

Oprea1_533384

Oprea1_633462

Prestwick0_000094

Prestwick1_000094

Prestwick2_000094

Prestwick3_000094

Prestwick_41

S1721_Selleck

SAM002589938

SDCCGMLS-0065415.P001

SMR000427366

SPBio_000255

SPBio_001987

SPECTRUM1500133

STK831906

STOCK1S-20293

STOCK1S-27186

Spectrum2_000068

Spectrum3_000308

Spectrum4_000243

Spectrum5_000848

Spectrum_000064

Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)

UNII-MRK240IY2L

WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW

ZINC04258316

[Methyl(nitroimidazolyl)mercaptopurine]

azathioprine

azatiopr in

cMAP_000046

17

Certolizumab pegol

approved

117

428863-50-7

Synonyms:

428863-50-7

CDP870

Certolizumab pegol

Certolizumab pegol (USAN/INN)

Certolizumab pegol (genetical recombination)

Certolizumab pegol (genetical recombination) (JAN)

Cimzia

D03441

18

Adalimumab

approved

443

331731-18-1

16219006

Synonyms:

331731-18-1

Adalimumab

Adalimumab (USAN/INN)

Adalimumab (genetical recombination)

Adalimumab (genetical recombination) (JAN)

D02597

Humira

Humira (TN)

Humira Pen

Ig gamma-1 chain C region

19

Methotrexate

approved

1444

1959-05-2, 59-05-2

126941

Synonyms:

4-amino-10-methylfolic acid

4-amino-N(10)-Methylpteroylglutamic acid

Abitrexate

Amethopterin

Amethopterine

Antifolan

Arbitrexate

Emtexate

Folex

HDMTX

L-Amethopterin

Ledertrexate

MTX

Metatrexan

Methopterin

Methotextrate

Methotrate

Methotrexat

Methotrexate

Methotrexate Sodium

Methotrexatum

Methylaminopterin

Methylaminopterinum

Metoject

Metotrexato

Mexate

Méthotrexate

N-Bismethylpteroylglutamic Acid

N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid

Otrexup

Rasuvo

Rheumatrex

Rheumatrex Dose Pack

Trexall

20

Infliximab

approved

349

170277-31-3

Synonyms:

Ig gamma-1 chain C region

Inflectra

Remicade

Remsima

21

Acetylcholine

experimental

689

51-84-3

187

Synonyms:

ACh

Acetyl choline ion

Acetylcholine Chloride

Acetylcholine cation

Acetylcholinium: acetyl-Choline

Choline acetate

Choline acetate (ester)

Miochol E

O-Acetylcholine

acetylcholine chloride

22

IncobotulinumtoxinA

599

23

Botulinum Toxins

616

24

Cholinergic Agents

3243

25

Neuromuscular Agents

922

26

AbobotulinumtoxinA

588

27

Neurotransmitter Agents

14795

28

OnabotulinumtoxinA

588

29

Peripheral Nervous System Agents

18510

30

Botulinum Toxins, Type A

588

31

6-Mercaptopurine

185

32

Adjuvants, Immunologic

1783

33

Acidophilus

Nutraceutical

482

Interventional clinical trials:

(show top 50) (show all 118)

id	Name	Status	NCT ID	Phase
1	Measles, Mumps, and Rubella (MMR) Immunity in College Students	Completed	NCT00962819	Phase 4
2	Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00126997	Phase 4
3	Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine	Completed	NCT00313950	Phase 4
4	Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis	Completed	NCT00731965	Phase 4
5	MMR Vaccination Among HIV-infected Adults	Completed	NCT02724852	Phase 4
6	Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.	Completed	NCT00388440	Phase 4
7	Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)	Completed	NCT00312858	Phase 4
8	Safety Study of a Refrigerator-Stable Formulation of VARIVAX®	Completed	NCT00432731	Phase 4
9	MMR and Varicella Vaccine in Premature Infants	Completed	NCT00156559	Phase 4
10	Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children	Completed	NCT02253407	Phase 4
11	Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV	Completed	NCT00329251	Phase 4
12	Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations	Recruiting	NCT01777529	Phase 4
13	Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR	Recruiting	NCT02325310	Phase 4
14	Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients	Recruiting	NCT01770119	Phase 4
15	The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine	Enrolling by invitation	NCT02153866	Phase 4
16	Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines	Terminated	NCT00138255	Phase 4
17	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)	Completed	NCT00092391	Phase 3
18	Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers	Completed	NCT01188343	Phase 3
19	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00127023	Phase 3
20	Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)	Completed	NCT01536405	Phase 3
21	Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older	Completed	NCT02058563	Phase 3
22	Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136	Completed	NCT00751348	Phase 3
23	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases	Completed	NCT00127010	Phase 3
24	Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM	Completed	NCT00969436	Phase 3
25	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life	Completed	NCT01681992	Phase 3
26	Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age	Completed	NCT02184572	Phase 3
27	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age	Completed	NCT01621802	Phase 3
28	Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)	Completed	NCT00092430	Phase 3
29	Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers	Completed	NCT00422292	Phase 3
30	ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)	Completed	NCT00975507	Phase 3
31	Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age	Completed	NCT01702428	Phase 3
32	Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)	Completed	NCT00985153	Phase 3
33	Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children	Completed	NCT00197015	Phase 3
34	Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine	Completed	NCT00406211	Phase 3
35	A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)	Completed	NCT00985166	Phase 3
36	Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study	Completed	NCT00326183	Phase 3
37	Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly	Completed	NCT00432042	Phase 3
38	Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers	Completed	NCT00483574	Phase 3
39	Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox	Completed	NCT00226499	Phase 3
40	ProQuad® rHA Safety	Completed	NCT00560755	Phase 3
41	Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children	Completed	NCT00192491	Phase 3
42	Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines	Completed	NCT00984295	Phase 3
43	Comparative Study of Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHA	Completed	NCT00566527	Phase 3
44	V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)	Completed	NCT00109343	Phase 3
45	ProQuad® Intramuscular vs Subcutaneous	Completed	NCT00402831	Phase 3
46	Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children	Completed	NCT01506193	Phase 3
47	Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers	Completed	NCT00626327	Phase 3
48	Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route	Completed	NCT00432523	Phase 3
49	Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children	Completed	NCT00474266	Phase 3
50	A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers	Completed	NCT00384397	Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

Sources:
³³MalaCards, ¹⁶FMA
See all MalaCards sources

MalaCards organs/tissues related to Mumps:

³³

Salivary gland, Brain, Breast, Heart, Testes, B cells, Prostate

FMA organs/tissues related to Mumps:

¹⁶

Salivary gl

Animal Models for Mumps or affiliated genes

Sources:
³⁸MGI
See all MalaCards sources

MGI Mouse Phenotypes related to Mumps:

³⁸

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	liver/biliary system	MP:0005370	7.9	FADD, IFNG, IL10RB, IL12RB2, IL6, STAT1
2	endocrine/exocrine gland	MP:0005379	7.7	CD40LG, FADD, IFNG, IL10RB, IL12RB2, IL6
3	digestive/alimentary	MP:0005381	7.4	FADD, IFNG, IL10RB, IL12RB2, IL2RA, IL6
4	hematopoietic system	MP:0005397	6.0	CD40LG, FADD, IFNG, IL10RB, IL12RB2, IL18R1
5	immune system	MP:0005387	5.7	CD40LG, FADD, IFNG, IL10RB, IL12RB2, IL18R1

Publications for Mumps

Sources:
⁵⁴PubMed
See all MalaCards sources

Articles related to Mumps:

(show top 50) (show all 750)

id	Title	Authors	Year
1	Emerging mumps infection. (27097351)	Rubin S.... Poland G.	2016
2	Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9a88months of age: a phase III, randomised, non-inferiority trial. (26362659)	Lalwani S.... Henry O.	2015
3	Seroprevalence of measles, mumps and rubella among young adults, after 20A years of universal two-dose MMR vaccination in Israel. (25891446)	Levine H.... Balicer R.D.	2015
4	Measles-Mumps-Rubella-Varicella Combination Vaccine (ProQuad(Ar)): A Guide to Its Use in Children in the EU. (25732634)	Scott L.J.	2015
5	Mumps outbreak in the Federation of Bosnia and Herzegovina with large cohorts of susceptibles and genetically diverse strains of genotype G, Bosnia and Herzegovina, December 2010 to September 2012. (25166347)	Hukic M.... Hubschen J.M.	2014
6	Mumps serum antibody levels before and after an outbreak to assess infection and immunity in vaccinated students. (25734169)	Gouma S.... VAN Binnendijk R.S.	2014
7	Increased levels of cytokines in cerebrospinal fluid of children with aseptic meningitis caused by mumps virus and echovirus 30. (24313836)	Sulik A.... Oldak E.	2014
8	Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. (25734162)	Fiebelkorn A.P.... Rubin S.	2014
9	Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. (24252695)	Livingston K.A.... Zimmerman C.M.	2014
10	Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella. (24412300)	Streng A.... Liese J.G.	2014
11	Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. (23574767)	Kumakura S.... Hirose M.	2014
12	Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. (23246259)	Freitas D.R.... Hatch D.L.	2013
13	Influence of Vaccination dose and clinico-demographical factors on antibody titers against measles, rubella, mumps, and varicella-zoster viruses among university students in Japan. (24270137)	Takeuchi J.... Hiraide A.	2013
14	Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. (24091837)	Takla A.... Koch J.	2013
15	Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. (23661802)	Waaijenborg S.... Wallinga J.	2013
16	Characterisation of mumps virus genotype C among patients with mumps in India. (23883719)	Jeevan M.... Thangam M.	2013
17	Spermiogram part of population with the manifest orchitis during an ongoing epidemic of mumps. (22937687)	Gazibera B.... Muratovic P.	2012
18	Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines. (23115712)	Shahkarami M.K.... Mohammadi A.	2012
19	Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations? (22687578)	Eriksen J.... Pebody R.	2012
20	Acupuncture for mumps in children. (22972121)	He J.... Jiang H.	2012
21	Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine. (23157791)	Gunatheesan S.... Moosa Y.	2012
22	Seroprevalence of measles, mumps, rubella, varicella-zoster and hepatitis A-C in Emirati medical students. (23217121)	Sheek-Hussein M.... Souid A.K.	2012
23	Mumps exposure of a health care provider working in a neonatal intensive care unit leads to a hospital-wide effort that prevented an outbreak. (21641085)	Gilroy S.A.... Stahl R.	2011
24	Mumps virus encephalitis with symmetric claustrum lesions. (21659481)	Ishii K.... Tamaoka A.	2011
25	A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein. (20727167)	Herrera E.... BarrA^n B.	2010
26	Lower long-term immunogenicity of mumps component after MMR vaccine. (20975455)	De Laval F.... Simon F.	2010
27	Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. (20587679)	Klein N.P.... Weintraub E.	2010
28	Closer look at autism and the measles-mumps-rubella vaccine. (21071320)	Hensley E.... Briars L.	2010
29	Mumps vaccine effectiveness in highly immunized populations. (20226249)	DomA-nguez A.... Jansa J.M.	2010
30	Molecular differences between two Jeryl Lynn mumps virus vaccine component strains, JL5 and JL2. (19656963)	Chambers P.... Duprex W.P.	2009
31	An office-based prospective study of deafness in mumps. (19209100)	Hashimoto H.... Kinumaki H.	2009
32	Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. (19007835)	Gillet Y.... Willems P.	2009
33	Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonist. (19625458)	Young D.F.... Randall R.E.	2009
34	Mumps: not an innocent bystander in solid organ transplantation. (19563333)	Baas M.C.... Bemelman F.J.	2009
35	Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. (19366435)	Gillet Y.... Fiquet A.	2009
36	Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. (19215718)	Roberts C.... Hart J.	2009
37	Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. (18440578)	Johnson J.B.... Parks G.D.	2008
38	Detection of mumps virus RNA by real-time one-step reverse transcriptase PCR using the LightCycler platform. (18945836)	Leblanc J.J.... Hatchette T.F.	2008
39	The role of air travel in the spread of mumps. (18831704)	Marienau K.J.... Redd S.	2008
40	Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. (17498856)	Park D.W.... Kim M.J.	2007
41	Assessing participation bias in a population-based study of measles-mumps-rubella vaccine immunity in children and adolescents aged 12-18. (17564596)	St Sauver J.L.... Poland G.A.	2007
42	Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). (17502347)	Bernstein H.H.... Kuter B.J.	2007
43	Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. (15655774)	Ovsyannikova I.G.... Poland G.A.	2005
44	Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. (15717298)	Fioredda F.... Castagnola E.	2005
45	Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies. (15042662)	Jalal H.... Brink N.	2004
46	The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. (12435771)	da Silveira C.M.... Prevots D.R.	2002
47	Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. (10390298)	Lindberg B.... Ivarsson S.A.	1999
48	Mumps pancreatitis without parotitis. (4692679)	Naficy K.... Ghadimi H.	1973
49	LEUKEMOID REACTION TO MUMPS VIRUS. (14160741)	Garcia R.... RASCH C.A.	1964
50	Mumps meningoencephalitis with and without parotitis. (18147966)	KILHAM L.	1949

Genes related to Mumps

Sources:
²⁰GeneCards, ¹²DISEASES, ⁴⁷Novoseek
See all MalaCards sources

Genes related to Mumps:

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication	PubmedIds
1	STAT2	Signal Transducer And Activator Of Transcription 2	36.76	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications, Drugs & Compounds (show sections)	16051811
2	STAT1	Signal Transducer And Activator Of Transcription 1	29.88	Novoseek inferred ⁴⁷ GeneCards inferred via : Publications, Drugs & Compounds (show sections)	12917439, 16051811
3	CD40LG	CD40 Ligand	25.40	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
4	IFNG	Interferon, Gamma	21.48	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
5	IL12RB2	Interleukin 12 Receptor Subunit Beta 2	21.37	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
6	IL18R1	Interleukin 18 Receptor 1	21.30	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
7	IRF2	Interferon Regulatory Factor 2	21.26	Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	8981353
8	IL2RA	Interleukin 2 Receptor Subunit Alpha	21.21	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
9	IL10RB	Interleukin 10 Receptor Subunit Beta	21.09	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
10	BST2	Bone Marrow Stromal Cell Antigen 2	21.07	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
11	IL6	Interleukin 6	20.67	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
12	FADD	Fas Associated Via Death Domain	18.24	GeneCards inferred via : Disorders (show sections)
13	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	17.74	GeneCards inferred via : Publications (show sections)

Variations for Mumps

Expression for genes affiliated with Mumps

Sources:
¹⁷Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Mumps.

Pathways for genes affiliated with Mumps

Sources:
⁵²PathCards, ³¹KEGG, ⁶²Thomson Reuters, ³⁹NCBI BioSystems Database, ⁵³PharmGKB, ⁵⁷Reactome, ⁵⁶R&D Systems, ⁵⁵QIAGEN
See all MalaCards sources

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show all 46)

id	Super pathways	Score	Top Affiliating Genes
1	Osteoclast differentiation³¹	9.7	IFNG, STAT1, STAT2
2	Immune response IFN gamma signaling pathway⁶² Show member pathways IFN-gamma pathway³⁹	9.7	IFNG, STAT1, STAT2
3	Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics⁵³ Show member pathways Inhibition of PKR⁵⁷	9.5	IL10RB, STAT1, STAT2
4	IL2-mediated signaling events³⁹ Show member pathways IL-2 Signaling pathway³⁹	9.5	IFNG, IL2RA, STAT1
5	Inflammatory Response Pathway³⁹	9.5	CD40LG, IFNG, IL2RA
6	Calcineurin-regulated NFAT-dependent transcription in lymphocytes³⁹ Show member pathways Calcium signaling in the CD4+ TCR pathway³⁹	9.5	CD40LG, IFNG, IL2RA
7	Th2 Differentiation Pathway⁵⁶	9.4	IFNG, IL12RB2, IL2RA
8	Innate Lymphoid Cell Differentiation Pathways⁵⁶	9.4	IFNG, IL12RB2, IL2RA
9	CXCR4-mediated signaling events³⁹	9.4	HLA-DRB1, STAT1, STAT2
10	Adipogenesis³⁹	9.3	IL6, STAT1, STAT2
11	Glucocorticoid receptor regulatory network³⁹	9.3	IFNG, IL6, STAT1
12	Colorectal Cancer Metastasis⁵⁵	9.3	IFNG, IL6, STAT1
13	Th17 Differentiation Pathway⁵⁶ Show member pathways IL-21 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types⁵⁶	9.3	IFNG, IL6, STAT1
14	Type II interferon signaling (IFNG)³⁹	9.3	IFNG, IRF2, STAT1, STAT2
15	Malaria³¹	9.3	CD40LG, IFNG, IL6
16	Interleukin-6 family signaling⁵⁷ Show member pathways IL-6-type cytokine receptor ligand interactions⁵⁷ Interleukin-6 signaling⁵⁷	9.3	IL12RB2, IL6, STAT1
17	Dendritic Cells Developmental Lineage Pathway⁵⁶	9.2	IFNG, IL6, IRF2
18	TSLP Signaling Pathway³⁹	9.2	IL2RA, IL6, STAT1
19	IgA-Producing B Cells in the Intestine⁵⁶	9.2	CD40LG, IL2RA, IL6
20	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers⁵⁶	9.1	IFNG, IL2RA, IL6
21	Immune response_IL-12 signaling pathway⁶² Show member pathways Interleukin-12 signaling⁵⁷	9.1	IFNG, IL12RB2, IL18R1, IL2RA
22	Interferon Pathway⁵⁵	9.0	IFNG, IL6, STAT1, STAT2
23	Rheumatoid arthritis³¹	9.0	HLA-DRB1, IFNG, IL6
24	Cytokines and Inflammatory Response³⁹	9.0	HLA-DRB1, IFNG, IL6
25	Hematopoietic cell lineage³¹	8.9	HLA-DRB1, IL2RA, IL6
26	IL12 signaling mediated by STAT4³⁹	8.9	HLA-DRB1, IFNG, IL18R1, IL2RA
27	TNF signaling pathway³¹	8.7	FADD, IL18R1, IL6
28	Toxoplasmosis³¹ Show member pathways Leishmaniasis³¹	8.6	CD40LG, HLA-DRB1, IFNG, IL10RB, STAT1
29	Immune response Antigen presentation by MHC class II⁶² Show member pathways G-protein signaling N-RAS regulation pathway⁶² Immune response IL-22 signaling pathway⁶² IL-22 Pathway⁵⁵	8.5	HLA-DRB1, IL10RB, IL12RB2, IL2RA, STAT1
30	Immune response IL-23 signaling pathway⁶² Show member pathways Development PDGF signaling via STATs and NF-kB⁶² Immune response IL-10 signaling pathway⁶² Development Angiopoietin - Tie2 signaling⁶² Angiopoietin-TIE2 Signaling⁵⁵ Angiopoietin receptor Tie2-mediated signaling³⁹ IL23-mediated signaling events³⁹	8.5	IFNG, IL10RB, IL18R1, IL6, STAT1
31	IL27-mediated signaling events³⁹ Show member pathways Th1 Differentiation Pathway⁵⁶ IL-12 Family Signaling Pathways⁵⁶	8.4	IFNG, IL12RB2, IL18R1, IL6, STAT1, STAT2
32	IL12-mediated signaling events³⁹ Show member pathways Immune response IL-12-induced IFN-gamma production⁶²	8.3	HLA-DRB1, IFNG, IL12RB2, IL18R1, IL2RA, STAT1
33	Interferon gamma signaling⁵⁷ Show member pathways Interferon Signaling⁵⁷ Regulation of IFNG signaling⁵⁷	8.2	BST2, HLA-DRB1, IFNG, IRF2, STAT1, STAT2
34	Toll-like receptor signaling pathway³⁹ ³¹ Show member pathways Chagas disease (American trypanosomiasis)³¹ Regulation of toll-like receptor signaling pathway³⁹ Hepatitis B³¹	8.2	FADD, IFNG, IL6, STAT1, STAT2
35	Immune response IFN alpha/beta signaling pathway⁶² Show member pathways Interferon alpha/beta signaling⁵⁷ Cytokine Network⁵⁵ Regulation of IFNA signaling⁵⁷	8.1	BST2, IFNG, IL6, IRF2, STAT1, STAT2
36	PAK Pathway⁵⁵ Show member pathways Epithelial Adherens Junctions⁵⁵ Antioxidant Action of Vitamin-C⁵⁵	8.0	CD40LG, IL10RB, IL12RB2, IL18R1, IL2RA, IL6
37	Jak/STAT Signaling Pathway⁵⁶	7.8	IFNG, IL10RB, IL12RB2, IL2RA, IL6, STAT1
38	Jak-STAT signaling pathway³¹ Show member pathways Type III interferon signaling³⁹ Interleukin-19, 20, 22, 24⁵⁷ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types⁵⁶ B-Cell Development⁵⁵	7.8	IFNG, IL10RB, IL12RB2, IL2RA, IL6, STAT1
39	PEDF Induced Signaling⁵⁵ Show member pathways IL-6 Pathway⁵⁵ Endothelin-1 Signaling Pathway⁵⁵ Cytokine-cytokine receptor interaction³¹ STAT3 Pathway⁵⁵ Glucocorticoid Receptor Signaling⁵⁵ all-trans-Retinoic Acid Signaling in Brain⁵⁵ NFAT Signaling and Lymphocyte Interactions⁵⁵ MIF Regulation of Innate Immune Cells⁵⁵ MIF Mediated Glucocorticoid Regulation⁵⁵ RAR-Gamma-RXR-Alpha Degradation⁵⁵ PGC1Alpha Pathway⁵⁵	7.7	CD40LG, IFNG, IL10RB, IL12RB2, IL18R1, IL2RA
40	TGF-Beta Pathway⁵⁵ Show member pathways JNK Pathway⁵⁵ MAPK Family Pathway⁵⁵ JAK-STAT Pathway⁵⁵ Regulation of eIF4 and p70S6K⁵⁵ SOCS Pathway⁵⁵	7.5	IFNG, IL10RB, IL12RB2, IL18R1, IL2RA, IL6
41	Tuberculosis³¹	7.5	FADD, HLA-DRB1, IFNG, IL10RB, IL6, STAT1
42	Influenza A³¹ Show member pathways Herpes simplex infection³¹ Measles³¹	7.3	FADD, HLA-DRB1, IFNG, IL2RA, IL6, STAT1
43	ERK Signaling⁵⁵ Show member pathways Molecular Mechanisms of Cancer⁵⁵ Rho Family GTPases⁵⁵ ILK Signaling⁵⁵ MAPK Signaling⁵⁵	6.7	CD40LG, FADD, IL10RB, IL12RB2, IL18R1, IL2RA
44	Akt Signaling⁵⁵ Show member pathways Tec Kinases Signaling⁵⁵ p38 Signaling⁵⁵	6.7	CD40LG, FADD, IL10RB, IL12RB2, IL18R1, IL2RA
45	Allograft rejection³⁹ ³¹ Show member pathways Antigen processing and presentation³¹ Viral myocarditis³¹ Intestinal immune network for IgA production³¹ CTL Mediated Apoptosis⁵⁵ THC Differentiation Pathway⁵⁵ Allograft Rejection³⁹ Asthma³¹ Autoimmune thyroid disease³¹ Type I diabetes mellitus³¹ Graft-versus-host disease³¹ Inflammatory bowel disease (IBD)³¹	6.1	CD40LG, FADD, HLA-DRB1, IFNG, IL10RB, IL12RB2
46	Immune System⁵⁷ Show member pathways Innate Immune System⁵⁷ Adaptive Immune System⁵⁷	5.0	BST2, CD40LG, FADD, HLA-DRB1, IFNG, IL10RB

GO Terms for genes affiliated with Mumps

Sources:
¹⁸Gene Ontology
See all MalaCards sources

Cellular components related to Mumps according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.0	CD40LG, HLA-DRB1, IL6

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 9)

id	Name	GO ID	Score	Top Affiliating Genes
1	regulation of type I interferon-mediated signaling pathway	GO:0060338	10.6	STAT1, STAT2
2	neutrophil apoptotic process	GO:0001781	10.2	IFNG, IL6
3	antigen processing and presentation	GO:0019882	10.1	HLA-DRB1, IFNG
4	defense response to protozoan	GO:0042832	10.1	IFNG, IL6
5	T cell homeostasis	GO:0043029	9.6	FADD, IL2RA
6	apoptotic process	GO:0006915	8.7	FADD, IFNG, IL2RA, STAT1
7	cytokine-mediated signaling pathway	GO:0019221	8.4	BST2, HLA-DRB1, IFNG, IL6, STAT1, STAT2
8	defense response to virus	GO:0051607	7.8	FADD, IFNG, IL10RB, IL6, STAT1, STAT2
9	immune response	GO:0006955	7.5	HLA-DRB1, IFNG, IL10RB, IL18R1, IL2RA, IL6